Michael York

Michael York

Auto-generated profile, based on publicly available information

Michael York

Division of Rheumatology, Boston University Medical Center, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2007 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MYMichael R. York
Michael R. York
TNTaro Nagai
Taro Nagai
AMAlyson J. Mangini
Alyson J. Mangini
RLRaphaël Lemaire
Raphaël Lemaire
JSJean Maguire van Seventer
Jean Maguire van Seventer
RLRobert Lafyatis
Robert Lafyatis
Objective: Microarray analyses of peripheral blood leukocytes have shown that patients with systemic lupus erythematosus express increased levels of type I interferon (IFN)–regulated genes. In this study we examined gene expression by peripheral blood mononuclear cells (PBMCs) from patients with systemic sclerosis (SSc) to better understand the dysregulation of the immune system in this disease.Methods: PBMC gene expression was analyzed by microarray and confirmed by real‐time polymerase chain reaction (PCR). Surface protein expression of Siglec‐1 was analyzed by flow cytometry in PBMCs from healthy control subjects and patients with SSc, and in control PBMCs that were cultured in vitro with Toll‐like receptor (TLR) agonists.Results: SSc patients showed increased expression of a cluster of IFN‐regulated genes, including Siglec‐1 (CD169, sialoadhesin). This result was verified and extended by real‐time PCR, showing that a subset of the SSc patients expressed strikingly increased levels of Siglec‐1 messenger RNA (mRNA). Flow cytometry of PBMCs from SSc patients and healthy controls showed increased Siglec‐1 surface protein expression, which was restricted to CD14+ monocytes. In vitro studies showed that type I IFN and certain TLR agonists, including TLR‐7 and TLR‐9, induced Siglec‐1 mRNA and protein expression. Moreover, TLR induction of surface Siglec‐1 was shown to be type I IFN–dependent. Increased numbers of Siglec‐1+ cells were observed by immunohistochemistry in the skin of SSc patients compared with healthy controls.Conclusion: Increased expression of Siglec‐1 in circulating SSc monocytes and tissue macrophages suggests that type I IFN–mediated activation of monocytes occurs in SSc, possibly through TLR activation of IFN secretion. These observations indicate a potential role for type I IFN–activated monocyte/macrophages in the pathogenesis of SSc.

29 January 2009 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
RLRobert Lafyatis
Robert Lafyatis
EKEugene Kissin
Eugene Kissin
MYMichael York
Michael York
GFGiuseppina Farina
Giuseppina Farina
KVKerry Viger
Kerry Viger
RSRobert W. Simms
Robert W. Simms
Objective: To determine the safety of rituximab, to provide preliminary data regarding the potential efficacy of rituximab, and to investigate the effects of rituximab on autoimmunity and fibrosis in patients with diffuse cutaneous systemic sclerosis (dcSSc).Methods: Fifteen patients with dcSSc, all of whom experienced their first non–Raynaud's disease–associated disease manifestation within 18 months of trial entry, were recruited to receive 2 intravenous doses of rituximab (1,000 mg), administered 2 weeks apart. Safety, clinical, and exploratory outcomes were evaluated at baseline and at 6 months. The primary outcome was the change in the modified Rodnan skin thickness score (MRSS) at 6 months compared with baseline.Results: Adverse events included frequent infusion reactions and rare infections (urinary tract infection and dental abscess occurred in 1 patient each). The mean change in the MRSS between baseline and 6 months was not significant. Results of pulmonary function tests and other measures of major organ involvement were stable. The modest B cell infiltrates that were present in most skin biopsy specimens at baseline were completely depleted at 6 months in most patients. Autoantibody titers showed only modest and variable changes after treatment.Conclusion: In this pilot study, treatment with rituximab appeared to be safe and well tolerated among patients with dcSSc. Rituximab treatment resulted in both depletion of circulating B cells and depletion of dermal B cells but had little effect on the levels of SSc‐associated autoantibodies. Rituximab treatment did not appear to result in a significant beneficial effect on skin disease. The potential efficacy of rituximab in other organs such as the lung could not be clearly evaluated in this small open‐label trial.

28 September 2006 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
RLRobert Lafyatis
Robert Lafyatis
MYMichael York
Michael York
AMAnn Marshak‐Rothstein
Ann Marshak‐Rothstein
Click on the article title to read more.

1 November 2010 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PDF file
GFGiuseppina A. Farina
Giuseppina A. Farina
MYMichael R. York
Michael R. York
MMMichael Di Marzio
Michael Di Marzio
CCCindy A. Collins
Cindy A. Collins
SMStephan Meller
Stephan Meller
RLRobert Lafyatis
Robert Lafyatis
Immune activation of fibrosis likely has a crucial role in the pathogenesis of systemic sclerosis (SSc). The aim of this study was to better understand the innate immune regulation and associated IFN- and transforming growth factor-β (TGFβ)-responsive gene expression in SSc skin and dermal fibroblasts, in particular the effect of different Toll-like receptor (TLR) ligands. To better understand the relationship between inflammation and fibrosis in vivo, we developed a murine model for chronic innate immune stimulation. We found that expression of both IFN- and TGFβ-responsive genes is increased in SSc skin and SSc fibroblasts when stimulated by TLR ligands. In contrast, cutaneous lupus skin showed much more highly upregulated IFN-responsive and much less highly upregulated TGFβ-responsive gene expression. Of the TLRs ligands tested, the TLR3 ligand, polyinosinic/polycytidylic acid (Poly(I:C)), most highly increased fibroblast expression of both IFN- and TGFβ-responsive genes as well as TLR3. Chronic subcutaneous immune stimulation by Poly(I:C) stimulated inflammation, and IFN- and TGFβ-responsive gene expression. However, in this model, type I IFNs had no apparent role in regulating TGFβ activity in the skin. These results suggest that TLR agonists may be important stimuli of dermal fibrosis, which is potentially mediated by TLR3 or other innate immune receptors.

28 February 2017 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
Antonella FarinaAntonella Farina
Antonella Farina
GPGiovanna Peruzzi
Giovanna Peruzzi
VLValentina Lacconi
Valentina Lacconi
SLStefania Lenna
Stefania Lenna
SQSilvia Quarta
Silvia Quarta
GFG. Alessandra Farina
G. Alessandra Farina
Monocytes/macrophages are activated in several autoimmune diseases, including systemic sclerosis (scleroderma; SSc), with increased expression of interferon (IFN)-regulatory genes and inflammatory cytokines, suggesting dysregulation of the innate immune response in autoimmunity. In this study, we investigated whether the lytic form of Epstein-Barr virus (EBV) infection (infectious EBV) is present in scleroderma monocytes and contributes to their activation in SSc. Monocytes were isolated from peripheral blood mononuclear cells (PBMCs) depleted of the CD19+ cell fraction, using CD14/CD16 negative-depletion. Circulating monocytes from SSc and healthy donors (HDs) were infected with EBV. Gene expression of innate immune mediators were evaluated in EBV-infected monocytes from SSc and HDs. Involvement of Toll-like receptor (TLR)8 in viral-mediated TLR8 response was investigated by comparing the TLR8 expression induced by infectious EBV to the expression stimulated by CL075/TLR8/agonist-ligand in the presence of TLR8 inhibitor in THP-1 cells. Infectious EBV strongly induced TLR8 expression in infected SSc and HD monocytes in vitro. Markers of activated monocytes, such as IFN-regulated genes and chemokines, were upregulated in SSc- and HD-EBV-infected monocytes. Inhibiting TLR8 expression reduced virally induced TLR8 in THP-1 infected cells, demonstrating that innate immune activation by infectious EBV is partially dependent on TLR8. Viral mRNA and proteins were detected in freshly isolated SSc monocytes. Microarray analysis substantiated the evidence of an increased IFN signature and altered level of TLR8 expression in SSc monocytes carrying infectious EBV compared to HD monocytes. This study provides the first evidence of infectious EBV in monocytes from patients with SSc and links EBV to the activation of TLR8 and IFN innate immune response in freshly isolated SSc monocytes. This study provides the first evidence of EBV replication activating the TLR8 molecular pathway in primary monocytes. Immunogenicity of infectious EBV suggests a novel mechanism mediating monocyte inflammation in SSc, by which EBV triggers the innate immune response in infected cells.

1 November 2009 in Current Opinion in Rheumatology
Verified
Journal Article
Closed access
RLRobert Lafyatis
Robert Lafyatis
MYMichael York
Michael York
Purpose of review Recent advances in our understanding of innate immunity and inflammation have direct bearing on how we understand autoimmunity, fibrosis and how innate immune sensors might stimulate both of these key features of systemic sclerosis (SSc) Recent findings Nucleic acid containing immune complexes activate toll-like receptors (TLRs) and induce expression of interferon responsive genes (IRGs) and autoantibodies in systemic lupus erythematosus (SLE). Recent studies indicate that increased SSc expression of IRGs may also be mediated by nucleic acid containing immune complexes. An expanding array of non-TLR innate immune pathways has recently been discovered. In particular, nalp3 mediated inflammasome activation of caspase-1 and conversion of pro-IL-1 to IL-1 play a key role in silica-mediated and bleomycin-mediated pulmonary fibrosis. TLR activation stimulates other inflammatory mediators, such as IL-1, IL-6 and TNFa in macrophages and dendritic cells. Activation of these and other inflammatory mediators, through TLR and non-TLR sensors, may cooperate to upregulate fibrotic mediators such as TGFβ and IL-13. Summary These observations provide a new paradigm for understanding the relationship between immunity/inflammation and fibrosis. New therapeutics, including TLR agonists and antagonists, and IFN inhibitors are currently under investigation. Further understandings of inflammasome-mediated fibrosis may provide further insights into SSc pathogenesis.